Neogen Corporation (NEOG)
NEOG trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-05-31, https://www.sec.gov/Archives/edgar/data/711377/000119312526326092/0001193125-26-326092-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-05-31.
Profile
| Field | Value |
|---|---|
| Ticker | NEOG on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | 1989 |
| SEC CIK | 0000711377 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | MI |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $870.4M |
| Net income | -$7.9M |
| Operating income | -$21.6M |
| Net margin | -0.9% |
| Operating margin | -2.5% |
| Revenue growth | -2.7% |
| Cash | $185.5M |
| Total assets | $3.3B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-07 |
| Cash and burn | $172.0M cash; operating cash flow $21.3M a quarter. | Report 2026-08-31 |
| Shares outstanding | 218,306,034 (2026-08-31); 217,298,626 a year earlier; 216,310,582 three years earlier. | Cover page 2026-08-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., Grand Rapids, Michigan, United States | PCAOB Form AP 2026-08-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $7K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-08-31 | $222.8M | -$11.9M | $12.9M | $172.0M | $1.6B | $884.0M | 10-Q 2026-10-07 |
| Q4 2026 2026-05-31 | $225.3M | -$11.3M | $30.2M | $185.5M | $793.7M | $870.4M | 10-K 2026-07-30 |
| Q3 2026 2026-02-28 | $211.2M | -$17.0M | $22.7M | $159.9M | $1.6B | $870.6M | 10-Q 2026-04-09 |
| Q2 2026 2025-11-30 | $224.7M | -$15.9M | $19.5M | $145.3M | $1.6B | $880.4M | 10-Q 2026-01-08 |
| Q1 2026 2025-08-31 | $209.2M | $36.3M | $10.8M | $138.9M | $1.6B | $887.0M | 10-Q 2026-10-07 |
| Q4 2025 2025-05-31 | $225.5M | -$612.2M | $16.4M | $129.0M | $894.1M | $894.7M | 10-K 2026-07-30 |
| Q3 2025 2025-02-28 | $221.0M | -$10.9M | $19.5M | $127.7M | $890.6M | $906.0M | 10-Q 2026-04-09 |
| Q2 2025 2024-11-30 | $231.3M | -$456.3M | $40.3M | $140.2M | $889.9M | $913.8M | 10-Q 2026-01-08 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2022-08-04 |
| Latest annual report | 10-K | 2026-07-30 |
| Latest quarterly / interim | 10-Q | 2026-10-07 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-09-28 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.5% |
| 1 month | -4.3% |
| 3 months | -5.6% |
| Year to date | +60.7% |
| 1 year | +76.3% |
| From 52-week high | -19.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CLDX | Celldex Therapeutics Inc. | $28.59 | -0.83% | $2.2B |
| NTLA | Intellia Therapeutics Inc. | $9.86 | +1.65% | $1.4B |
| LNTH | Lantheus Holdings Inc. | $101.72 | +0.13% | $6.7B |
| ORKA | Oruka Therapeutics Inc. | $99.24 | -5.80% | $6.7B |
| QDEL | QuidelOrtho Corporation | $10.21 | -4.93% | $700.5M |
| QUIT | Achieve Life Sciences Inc. Common Shares | $6.06 | -4.11% | $666.8M |
| NNNN | Anbio Biotechnology | $3.88 | +1.57% | $558.3M |
| MYGN | Myriad Genetics Inc. | $5.57 | -1.59% | $534.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier